A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Gout

Inclusion Criteria:

1. Gout participant (with a history of gout attack or concurrent gouty tophi) with SUAlevel greater than (>) 7.0 mg/dL in the screening phase (within 14 days prior torandomization)
2. Male or female participant with age greater than or equal to (>=) 18 years at the timeof informed consent
3. Provide written informed consent signed by the participant prior to entering the studyor undergoing any study procedures, indicating that they understand the purpose andprocedures required for the study and are willing to participate in the study

Exclusion Criteria:

1. Has gouty arthritis that has not resolved within 14 days prior to randomization
2. Has secondary hyperuricemia
3. Comorbidities with nephrolithiasis or clinical urinary calculi (example, haematuria,back pain)
4. Evidence of clinically significant disease (example, cardiac disease: heart failureand angina unstable, respiratory, gastrointestinal, renal, or neurological disease:cerebral infarction) that in the opinion of the investigator could affect theparticipant's safety or interfere with the study assessments
5. Evidence of clinical significant hepatic disease: refer to Grade 2 in the "SeriousnessGrading Criteria for Adverse Drug Reactions" or aspartate aminotransferase (AST) oralanine aminotransferase (ALT) >3 multiple (*) upper limit of normal (ULN) in thescreening phase
6. Estimated glomerular filtration rate (eGFR) of less than (<) 30 milliliter perminute/1.73 square meters in the screening phase
7. Systolic blood pressure of >=180 millimetre of mercury (mmHg) or diastolic bloodpressure of >=110 mmHg in the screening phase
8. Hemoglobin A1c National Glycohemoglobin Standardization Program (NGSP) value of >=8.4percent (%) in the screening phase
9. Hypersensitivity to the study drugs (dotinurad or febuxostat) or their excipients, orall of urine alkalinizer (potassium citrate/sodium citrate hydrate compoundpreparations)